PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel?
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 45 (5) , 101553
Abstract
No abstract availableKeywords
Funding Information
- Ligue Contre le Cancer
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales (12357)
This publication has 37 references indexed in Scilit:
- PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitrohepatocellular carcinoma modelsBMC Cancer, 2014
- Update on hepatocellular carcinoma breakthroughs: Poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategyClinics and Research in Hepatology and Gastroenterology, 2014
- Variations in the mRNA expression of poly(ADP‐ribose) polymerases, poly(ADP‐ribose) glycohydrolase and ADP‐ribosylhydrolase 3 in breast tumors and impact on clinical outcomeInternational Journal of Cancer, 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes Reverse Phase Protein Array DataPLOS ONE, 2012
- Hepatitis B virus X protein is essential to initiate and maintain virus replication after infectionJournal of Hepatology, 2011
- Targeting poly(ADP-ribose) polymerase activity for cancer therapyCellular and Molecular Life Sciences, 2010
- γH2AX and cancerNature Reviews Cancer, 2008
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004